|
Name: ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)
Type: Synthetic cannabinoid
AKA: ADB-FUBINACA
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
ADB-FUBINACA is a synthetic cannabinoid first identified in the 2010s. It is part of a new generation of synthetic cannabinoids designed to mimic the effects of THC. ADB-FUBINACA has been associated with numerous adverse health effects, including severe intoxication and fatalities. Its emergence highlights the ongoing challenges in regulating synthetic cannabinoids and preventing their misuse.
|
|
V. Legal Information
ADB-FUBINACA, a synthetic cannabinoid, is regulated under analog laws due to its potent effects and potential for abuse. In the US, it is covered under the Federal Analog Act if deemed similar to controlled substances. Globally, its legal status varies, with increasing restrictions reflecting efforts to control synthetic cannabinoids and address their public health impact.
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
ADB-FUBINACA, a synthetic cannabinoid, is known for its potent psychoactive effects. As an upper, it causes intense euphoria and altered perception. Short-term effects include anxiety and paranoia, while long-term use may lead to severe mental health issues. Overdose risks involve acute psychosis and cardiovascular problems. Safe use is challenging due to potency variability. Recent research highlights its high potency and associated health risks, emphasizing the need for regulation.  |
|
VII. Psychological Effects
ADB-FUBINACA, a synthetic cannabinoid, affects the endocannabinoid system, causing altered mood and cognition. Psychological effects include euphoria, anxiety, and hallucinations. Effects last several hours, with risks of severe mental health issues and dependence. Research focuses on its safety profile and psychological impact.
 |
|
VIII. Culture
ADB-FUBINACA, a synthetic cannabinoid, is part of the 'Spice' or 'K2' products marketed as legal alternatives to marijuana. Its cultural impact is tied to the growing concerns over synthetic cannabinoids, which are often sold as 'legal highs' but can have unpredictable and dangerous effects. The substance has contributed to the discourse on the risks associated with synthetic drugs, including severe health issues and legal challenges. ADB-FUBINACA underscores the complexities of synthetic drug regulation and the need for effective public health strategies to address the emerging challenges of synthetic cannabinoids in the drug market.
 |